Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.7717/peerj.9392 http://scihub22266oqcxt.onion/10.7717/peerj.9392 32587806!7301894!32587806     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       PeerJ 2020 ; 8 (ä): e9392 Nephropedia Template TP {{tp|p=32587806|t=2020. A potential role for Galectin-3 inhibitors in the treatment of COVID-19 |pdf=|usr=}}{{32587806}} gab.com Text A potential role for Galectin-3 inhibitors in the treatment of COVID-19 JO: PeerJ http://www.kidney.de/pget.php?&tw=1&pmid=32587806 #FOAvip The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), the causative agent of coronavirus disease 2019 (COVID-19), has been declared a global pandemic by the World Health Organization. With no standard of care for the treatment of COVID-19, there is an urgent need to identify therapies that may be effective in treatment. Recent evidence has implicated the development of cytokine release syndrome as the major cause of fatality in COVID-19 patients, with elevated levels of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) observed in patients. Galectin-3 (Gal-3) is an animal lectin that has been implicated in the disease process of a variety of inflammatory conditions. Inhibitors of the small molecule Gal-3 have been shown to reduce the levels of both IL-6 and TNF-alpha in vitro and have shown anti-inflammatory effects in vivo. Additionally, a key domain in the spike protein of beta-coronaviridae, a genus which includes SARS-CoV2, is nearly identical in morphology to human Gal-3. These spike proteins are critical for the virus' entry into host cells. Here we provide a systematic review of the available literature and an impetus for further research on the use of Gal-3 inhibitors in the treatment of COVID-19. Further, we propose a dual mechanism by which Gal-3 inhibition may be beneficial in the treatment of COVID-19, both suppressing the host inflammatory response and impeding viral attachment to host cells. Twit Text FOAVip A potential role for Galectin-3 inhibitors in the treatment of COVID-19 ????PeerJ http://www.kidney.de/pget.php?&tw=1&pmid=32587806 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32587806 #FOAvip English Wikipedia <ref>{{Cite pmid|32587806}}</ref> A potential role for Galectin-3 inhibitors in the treatment of COVID-19 #MMPMID32587806 Caniglia JL; Guda MR; Asuthkar S; Tsung AJ; Velpula KK PeerJ 2020[]; 8 (ä): e9392 PMID32587806show ga The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), the causative agent of coronavirus disease 2019 (COVID-19), has been declared a global pandemic by the World Health Organization. With no standard of care for the treatment of COVID-19, there is an urgent need to identify therapies that may be effective in treatment. Recent evidence has implicated the development of cytokine release syndrome as the major cause of fatality in COVID-19 patients, with elevated levels of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) observed in patients. Galectin-3 (Gal-3) is an animal lectin that has been implicated in the disease process of a variety of inflammatory conditions. Inhibitors of the small molecule Gal-3 have been shown to reduce the levels of both IL-6 and TNF-alpha in vitro and have shown anti-inflammatory effects in vivo. Additionally, a key domain in the spike protein of beta-coronaviridae, a genus which includes SARS-CoV2, is nearly identical in morphology to human Gal-3. These spike proteins are critical for the virus' entry into host cells. Here we provide a systematic review of the available literature and an impetus for further research on the use of Gal-3 inhibitors in the treatment of COVID-19. Further, we propose a dual mechanism by which Gal-3 inhibition may be beneficial in the treatment of COVID-19, both suppressing the host inflammatory response and impeding viral attachment to host cells. äA potential role for Galectin-3 inhibitors in the treatment of COVID-1(epmc).pdf DeepDyve Pubget Overpricing